Compare HP Inc (HPQ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Tango Therapeutics Inc. — how do they compare? HP Inc trades at $30.46 (market cap $27.62B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: HP Inc is far larger — about 7.4× Tango Therapeutics Inc.'s market cap, and HP Inc pays a 3.92% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and Tango Therapeutics Inc. for 0 Days on average.
| HPQ | TNGX | |
|---|---|---|
Market Cap | $27.62B | $3.75B |
Volume | 12,820,066 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $35.48 | $32.90 |
52-Week Low | $18.20 | $7.50 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $33.79B | $2.77B |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $30.46, up 1.98% today, with a bearish technical signal despite recent earnings beats. The company maintains stable cash flow generation ($460M net in 2025) and pays a $0.30 dividend, but faces PC market headwinds with 2027 industry volume declines projected. Valuation appears reasonable with P/E of 11.69 and P/S of 0.48, though negative shareholder equity raises concerns.
The outlook is mixed: attractive valuation and dividend yield support the stock, but PC market challenges and negative equity position create significant risks. Analyst consensus is cautious with a $25.75 price target below current levels, suggesting limited near-term upside potential amid industry uncertainty.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
